This site is intended for UK healthcare professionals

 
Sponsorship statement:
This video has been funded by the Boehringer Ingelheim (BI) & Lilly Alliance. The BI & Lilly Alliance has had no editorial input into or influence on the agenda, speaker selection or content of this video.
BI-logo-blue
Lilly

Masterclass: Advances in diagnosis and management of heart failure with preserved ejection fraction (HFpEF)

3 August 2023
Available for 1 CPD point(s)

Masterclass

Watch Professor Paul Kalra and Dr Patricia Campbell discuss the diagnostic challenges in heart failure with preserved ejection fraction and how it can be optimally managed with reference to the latest guidance and treatments
Speakers

Professor Paul Kalra Professor of Cardiology, Portsmouth Hospitals NHS Trust, UK
Dr Patricia Campbell Consultant Cardiologist and Heart Failure Clinical Lead, Southern Health and Social Care Trust, Northern Ireland

Learning objectives
  • The pathophysiology of HFpEF
  • How to diagnose it
  • The treatment and evidence base
  • What the future holds

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.

References

1. NICE. Heart failure – chronic. July 2023. Available from: https://cks.nice.org.uk/topics/heart-failure-chronic/ – :~:text=People with suspected heart failure,transthoracic echocardiography within 2 weeks. (accessed August 2023)

2. Jasinska-Piadlo A, Campbell P. Heart 2023;109:847–83 https://doi.org/10.1136/heartjnl-2022-321097

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.